How to Detect HPV and What a Positive Result Means

HPV is detected through molecular tests that look for the virus’s genetic material in cells collected from the cervix, throat, anus, or other sites, and a positive result means the virus is present in your body right now. That sounds alarming, but the critical context is that up to 90% of HPV infections clear on their own within two years, and most people who test positive will never develop cancer or even precancerous changes. What matters far more than the positive result itself is which type of HPV was found, whether your cells show any abnormal changes, and what your follow-up plan looks like.

What HPV Tests Actually Look For

There is no blood test for HPV that works as a routine screening tool. Instead, HPV detection relies on molecular techniques that identify viral DNA or RNA directly in a sample of cells. The most common approach is an HPV DNA test, which amplifies and detects genetic material from the virus. These tests can distinguish between high-risk HPV types, which are linked to cancers, and low-risk types, which cause conditions like genital warts but pose no cancer threat.¹ The distinction between high-risk and low-risk matters enormously for what happens next, because the two categories carry completely different implications.

A newer generation of tests targets HPV E6/E7 mRNA, which are molecules the virus produces when it is actively driving cells toward abnormal growth. One study at a tertiary care center found that the mRNA assay was more sensitive (96%) and more specific (about 93%) for detecting significant precancerous lesions than either HPV DNA testing or cytology alone.² The logic is straightforward: detecting that the virus is present (DNA test) is one thing, but detecting that it is actively producing cancer-promoting proteins (mRNA test) is a step closer to identifying who is actually at risk.

The traditional Pap smear, or cervical cytology, does not look for HPV at all. Instead, it examines cells under a microscope for abnormal changes. In many screening programs, the Pap smear and HPV test are used together (co-testing), or HPV testing is used first and cytology is added only if HPV is found. One large retrospective study found that Pap smears had higher specificity for detecting high-grade changes than HPV tests, meaning they were better at ruling out disease in people who did not have it, though HPV testing catches a broader net of infections.³ The trade-off is that HPV testing is very good at catching people who might have a problem but flags many who ultimately don’t, while cytology is more precise but misses some infections entirely.

High-Risk Versus Low-Risk Types

More than 200 types of HPV have been identified, but only about a dozen are classified as high-risk. HPV 16 and HPV 18 get the most attention because they cause the majority of HPV-related cancers. Other high-risk types include HPV 31, 33, 45, 52, and 58. Low-risk types, most famously HPV 6 and HPV 11, cause genital warts and benign lesions but do not lead to cancer.⁴

When your test result says “HPV positive,” the first thing to look for is whether it specifies the type. Many current screening tests report whether any high-risk type was detected and may specifically call out HPV 16 and 18, since those two carry the highest individual risk. A positive result for HPV 16 typically triggers more aggressive follow-up than a positive for, say, HPV 53. Some labs now test for a panel of high-risk types and report each one individually, while others give a pooled result that simply says “high-risk HPV detected.” Either way, a conversation with your clinician about which types were found is worth having.

Most Infections Clear Without Treatment

This is probably the single most important thing to understand about an HPV-positive result: the virus usually goes away on its own. About 43% of high-risk HPV infections clear within six months, and up to 90% resolve within two years.⁵ Your immune system handles the virus in most cases without you ever knowing it was there. The infections that do not clear, the persistent ones, are the ones that can eventually cause precancerous changes and, if left unmonitored, cancer. That process typically takes years to decades, which is why screening intervals of several years are considered safe for most people.

Several factors influence whether an infection persists. Older age plays a role: for every five-year increase in age, one study found a 15% decrease in the rate at which the virus clears, though this effect became apparent mainly after about 400 days of infection.⁶ Being infected with multiple HPV types at once also affects dynamics in complex ways, initially speeding clearance but complicating things over time. Other independent risk factors for persistent high-risk HPV infection include a high viral load, reproductive tract inflammation, and thyroid dysfunction.⁷

People living with HIV face a particularly challenging situation. HIV-related immune suppression reduces the body’s ability to clear HPV, creating conditions where multiple high-risk HPV types can persist and co-exist. This increases the risk of developing cervical lesions and makes the progression toward cancer faster and harder to manage. Emerging high-risk types like HPV 58, 70, and 56 are of special concern in this population because they show up more frequently and carry significant cancer-causing potential.⁸

What Happens After a Positive HPV Test

A positive HPV result does not mean you have cancer or even precancer. It means you need triage, a process of figuring out whether the infection is causing any cell changes worth investigating further. The standard next step depends on the screening system your provider uses.

If your screening started with an HPV test alone, the triage step usually involves cytology (a Pap smear on the same sample or a new one). If both the HPV test and the cytology are abnormal, you will likely be referred for colposcopy, a procedure where a clinician examines your cervix under magnification and may take small tissue samples (biopsies). If HPV is positive but your cytology is normal, you may be asked to return in a year for repeat testing, because the odds of a significant lesion developing in the short term are low.

One of the newer triage tools is p16/Ki-67 dual staining, a lab test run on your cervical cells that looks for two proteins whose simultaneous presence suggests the virus is actively interfering with cell growth. Because the vast majority of HPV infections are transient and will not cause precancer, the goal of triage is to avoid sending everyone with a positive HPV test straight to colposcopy.⁹ A large study found that women who tested positive on dual staining had a five-year risk of precancer of about 31%, while those who tested negative had a five-year risk of only about 8.5%, well below the threshold that would trigger a colposcopy referral.¹⁰ Another study reported that dual staining had about 89% sensitivity and 79% specificity for detecting precancerous lesions, and that combining it with cytology further improved performance while reducing unnecessary colposcopy referrals.¹¹

If biopsy results show precancerous changes, these are graded from mild (CIN1 or LSIL) to moderate or severe (CIN2/CIN3 or HSIL).¹² Mild changes often resolve on their own and may just be monitored. Moderate to severe changes are more likely to persist or progress and are usually treated, most commonly with a procedure called LEEP (loop electrosurgical excision procedure), which removes the abnormal tissue. After treatment, follow-up with HPV testing and cytology continues at regular intervals to watch for recurrence.¹³

Self-Collected Samples Are Closing the Access Gap

One of the biggest barriers to cervical cancer screening worldwide is the need for a clinical visit. Self-collection kits, which allow you to take a vaginal swab at home and mail it to a lab, have been gaining traction. A systematic review of 38 studies found that about 95% reported self-collected specimens provided sensitivity and specificity comparable to clinician-collected samples.¹⁴ A large study from the Netherlands found that the sensitivity for detecting significant precancerous changes (CIN3 or higher) was about 94% for self-collected samples compared to clinician-collected ones, with even slightly higher specificity.¹⁵

Acceptability rates for various self-sampling devices have ranged from about 84% to 100%, meaning most people who try them find the experience acceptable.¹⁴ A meta-analysis in African settings showed self-collected samples achieved sensitivities close to 80% and specificities close to 90% for detecting high-risk HPV, with point-of-care tests performing particularly well.¹⁶ From a cost perspective, mailing HPV self-test kits directly to people was found to be not only more effective at catching screening-overdue individuals but often cost-saving compared to standard care.¹⁷

HPV Detection Beyond the Cervix

HPV does not only affect the cervix. It is now the leading cause of oropharyngeal cancer (cancers of the back of the throat, base of the tongue, and tonsils), and it also plays a role in anal, penile, vaginal, and vulvar cancers. Detection methods for HPV-related head and neck cancers typically involve a biopsy of the tumor followed by a sequential testing strategy: first, a staining test for the p16 protein, and then, if positive, confirmation with HPV DNA testing. RNA-based tests that detect viral activity in tumor tissue are also emerging and may eventually work as standalone diagnostics.¹⁸ Liquid biopsies that detect HPV-related circulating tumor DNA in blood samples are showing early promise for monitoring oropharyngeal cancers, though they are not yet standard.¹⁸

For anal cancer screening, particularly in higher-risk groups like men who have sex with men and people living with HIV, co-testing with both cytology and high-risk HPV testing has shown strong results. In one Italian screening program, co-testing achieved 100% sensitivity and 100% negative predictive value for detecting significant anal precancer, meaning nobody with a negative co-test result had a lesion missed.¹⁹ Anal cancer screening is not as widely standardized as cervical screening, but guidelines are evolving, especially for high-risk populations.

The Testing Gap for Men

There is no approved routine HPV screening test for men the way there is for women. Men can carry and transmit the virus, develop genital warts from low-risk types, and develop cancers of the penis, anus, and throat from high-risk types, yet the infrastructure for detecting HPV in men lags behind. Limited testing methods and the absence of uniform medical guidelines remain major challenges.²⁰

The conventional approach involves urethral swabs, which are uncomfortable and not widely used outside of research settings. Researchers have been evaluating less invasive alternatives. In one study of 110 men, genital swabs detected HPV in about 68% of samples, significantly outperforming both urethral swabs and urine samples when used alone. Urine by itself was highly specific (100%, meaning if it said positive, it was truly positive) but not very sensitive (about 54%), meaning it missed many infections. However, combining a genital swab with a urine sample achieved near-perfect diagnostic performance, with sensitivity of about 99% and specificity of 100%.²¹ This combination could eventually become a practical, non-invasive option, though it has not been adopted into routine clinical practice yet.

The Emotional Weight of a Positive Result

The psychological impact of testing positive for HPV is real and often underappreciated by clinicians. A mixed-methods meta-analysis found that women who tested HPV-positive showed significantly higher short-term anxiety than those with normal results, regardless of whether their cytology was also abnormal. The emotional response also included feelings of disgust, shame, surprise, and fear about cancer, along with concerns about relationships, stigma, and confusion about what the result actually means.²²

A separate study looking specifically at women in routine primary HPV screening found that even those who tested HPV-positive with completely normal cytology, meaning their immediate cancer risk was very low, had significantly elevated anxiety compared to women who tested negative. Encouragingly, this anxiety appeared to normalize over time; women who received the same HPV-positive result at a 12-month follow-up did not show the same spike in anxiety as they had the first time around.²³

Much of the distress stems from misunderstanding what an HPV-positive result means. Research with Taiwanese women found that a major driver of psychosocial burden was stigma rooted in the belief that HPV infection implies having many sexual partners or being somehow at fault. Women described HPV as a “shameful disease” because of its sexually transmitted nature, and many had concerns about infidelity or feared spreading the virus.²⁴ The reality is that HPV is so common that most sexually active people will have it at some point. A positive result says almost nothing about your sexual history or your partner’s faithfulness. Qualitative research has found that women are generally reassured once they learn HPV is extremely common, often has no symptoms, can lie dormant for years, and usually clears on its own.²³ Getting that information early, ideally at the time you receive your result, makes a genuine difference.

How Vaccination Is Changing the Screening Landscape

Widespread HPV vaccination is a public health triumph, but it is creating an interesting complication for screening programs. As vaccination reduces the prevalence of the HPV types that cause most cervical precancer, the performance characteristics of screening tests shift. In vaccinated populations, there are fewer true precancerous lesions to find, which means any abnormal screening result is less likely to reflect real disease. A study of nearly 96,000 cytology records in Scotland found that HPV vaccination reduced the positive predictive value of cytology for detecting precancer by about 16%, meaning about 38% more women had to undergo colposcopy to find a single case of significant disease.²⁵

A Swedish cohort showed a similar pattern: the positive predictive value of high-grade cytology for detecting precancer dropped from about 70% in unvaccinated women to roughly 57% in those vaccinated before age 17.²⁶ This does not mean screening is less important for vaccinated people. It means screening programs need to adapt, potentially by relying more on HPV testing (which directly detects the virus) rather than cytology (which detects cell changes that are becoming rarer). It also means that if you were vaccinated and get a mildly abnormal screening result, the probability that it reflects serious disease is lower than the same result would be in an unvaccinated person.

HPV Testing During Pregnancy

If you are pregnant and due for cervical screening, or if you had an abnormal result before becoming pregnant, the question of HPV testing during pregnancy naturally arises. HPV DNA testing can be performed during pregnancy and serves as a useful tool for monitoring and risk-sorting. One study reported sensitivity of about 91% and a negative predictive value of about 96% for detecting significant precancerous changes during pregnancy.²⁷ However, the specificity can be lower, meaning false positives are more common. If needed, colposcopy-guided biopsy remains the gold standard for managing suspected cervical precancer during pregnancy, though treatment is typically deferred until after delivery unless invasive cancer is suspected.

Vaccination After Treatment for Precancer

A question that comes up frequently is whether getting vaccinated after you have already been treated for HPV-related precancer makes any difference. The evidence increasingly says yes. A retrospective study found that HPV vaccination was associated with roughly a 75% lower risk of high-grade precancer recurring after LEEP, and that getting vaccinated within six months of the procedure appeared to be the optimal window for preventing recurrence.²⁸ Another study found recurrence rates of about 4% in vaccinated patients compared with roughly 12% in unvaccinated patients after excisional treatment.²⁹ These are observational data, not randomized trials, so the numbers should be taken as encouraging rather than definitive. Still, if you have been treated for cervical precancer and have not been vaccinated, it is worth discussing with your doctor.